Focus on the PARITY Trial, with special guest Michelle Ghert, MD, FRCSC

In this episode, Marc and Mo are joined by special guest Michelle Ghert, MD, FRCSC (Professor of Surgery at McMaster University and President of the Musculoskeletal Tumor Society) in a discussion of the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) study that appeared in JAMA as well as the related JBJS supplement focusing on secondary analytic questions. 

Links: 

• PARITY Supplement in JBJS: https://bit.ly/47fEkqH 
• Editorial focusing on PARITY: https://bit.ly/44ExN6Z 
• Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators; Ghert M, Schneider P, Guyatt G, Thabane L, Vélez R, O'Shea T, Randall RL, Turcotte R, Wilson D, Wunder JS, Baptista AM, Cheng EY, Doung YC, Ferguson PC, Giglio V, Hayden J, Heels-Ansdell D, Khan SA, Sampath Kumar V, McKay P, Miller B, van de Sande M, Zumárraga JP, Bhandari M. Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial. JAMA Oncol. 2022 Mar 1;8(3):345-353. doi: 10.1001/jamaoncol.2021.6628. PMID: 34989778; PMCID: PMC8739829. https://bit.ly/3K7MG8S 

Subspecialties: 

• Infection 
• Oncology 
• Orthopaedic Essentials